XOMA Corp
NASDAQ:XOMA

Watchlist Manager
XOMA Corp Logo
XOMA Corp
NASDAQ:XOMA
Watchlist
Price: 33.88 USD 9.26% Market Closed
Market Cap: 399.1m USD
Have any thoughts about
XOMA Corp?
Write Note

Net Margin
XOMA Corp

-183.6%
Current
-363%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-183.6%
=
Net Income
-42.4m
/
Revenue
23.1m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
XOMA Corp
NASDAQ:XOMA
398.3m USD
-184%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
320.1B USD
9%
US
Amgen Inc
NASDAQ:AMGN
147.4B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.3B EUR
-14%
Country US
Market Cap 398.3m USD
Net Margin
-184%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 320.1B USD
Net Margin
9%
Country US
Market Cap 147.4B USD
Net Margin
13%
Country US
Market Cap 119.4B USD
Net Margin
-5%
Country US
Market Cap 113.8B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.4B AUD
Net Margin
18%
Country US
Market Cap 82.6B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.3B EUR
Net Margin
-14%
No Stocks Found

XOMA Corp
Glance View

Market Cap
398.3m USD
Industry
Biotechnology

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 12 full-time employees. The firm's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The firm's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The firm's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.

XOMA Intrinsic Value
34.97 USD
Undervaluation 3%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-183.6%
=
Net Income
-42.4m
/
Revenue
23.1m
What is the Net Margin of XOMA Corp?

Based on XOMA Corp's most recent financial statements, the company has Net Margin of -183.6%.